New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.
At the 5th annual Heart in Diabetes Conference hosted by The Metabolic Institute of America, investigators presented research on pharmacological interventions for individuals with diabetes who contract COVID-19 and use of monoclonal antibodies to prevent COVID-19 in patients with cardiovascular disease (CVD) and diabetes.
Aspirin Among Hospitalized Patients
In one abstract1 presented at the conference, researchers from Saudi Arabia outlined the statistically significant effects of aspirin administration among hospitalized patients with COVID-19, diabetes, and obesity.
“It is estimated that people with cardiovascular risk factors are more prone for mortality and intubation [for COVID-19], especially obesity, and this is especially true in Saudi Arabia and the region of Hail, where morbid obesity (body mass index [BMI] >30 kg/m2) is at 33.6% of the population,” the authors wrote.
In an effort to establish an epidemiological link between aspirin use, diabetes, and intubation, the researchers measured mortality rates and readmissions over 30 days at a hospital in Saudi Arabia.
A total of 753 patients, the majority of whom were male (n = 545), were included in the retrospective cohort study, which analyzed data from April 1, 2020, to July 31, 2020. Most participants were between the ages of 42 and 61, and all were admitted with positive COVID-19 tests.
Of those included, approximately 40% had diabetes, with 18% of these patients needing intubation compared with just 7% of nondiabetic patients. The researchers found that, compared with those who took aspirin during their stay, those who did not receive aspirin had higher mortality and intubation rates, median intensive care unit (ICU) length of stay, and readmission rates.
In addition, “significant correlation was documented between BMI and days of ICU stay (P <.005),” the authors wrote, adding “in the global chronic disease syndrome with obesity and diabetes, the anti-aging gene may be repressed and the patients may be at risk for programmed cell death.”
Monoclonal Antibodies to Prevent COVID-19
Additional research2 presented at the meeting found administration of Regeneron’s REGEN-COV monoclonal antibody combination (casirivimab and imdevimab) reduced the risk of developing COVID-19 in participants with CVD and/or diabetes regardless of serostatus, and was generally well tolerated.
“There is an unmet need for treatment options for individuals who are at an increased risk of moderate/severe COVID-19, including those with CVD and/or diabetes,” the authors wrote.
Previous studies have shown the monoclonal combination reduced COVID-19–related hospitalizations or death in symptomatic patients with COVID-19 and has prevented symptomatic infection in seronegative individuals compared with a placebo.
Investigators conducted a post hoc subgroup analysis of patients with CVD and/or diabetes, who were uninfected with COVID-19 at baseline but lived in the same house as an infected individual.
A total of 366 uninfected and seronegative participants were included in the study, which took place across centers in the United States, Romania, and Moldova. All participants had CVD and/or diabetes, a mean age of 55.5 years, and mean BMI of 31 kg/m2.
To carry out the study, “uninfected (RT-qPCR-negative) individuals ≥12 years of age were randomized 1:1 to receive a single dose of REGEN-COV 1200 mg SC (600 mg casirivimab and 600 mg imdevimab) or placebo within 96 hours of the index case being diagnosed SARS-CoV-2 positive,” the authors explained.
Analyses revealed:
The trial took place prior to the wide circulation of the delta COVID-19 variant. Although outside the study window, 3 participants died due to cardiac arrest, congestive heart failure, and sudden death.
Overall, results indicate “REGEN-COV represents an easy-to-administer option for the prevention of COVID-19 in high-risk persons, as a complement to vaccines,” the authors wrote. “Treatment with REGEN-COV reduced the risk of developing symptomatic disease, protecting vulnerable groups who have been in contact with an index case,” they concluded.
Five of the study authors are Regeneron employees.
References:
1. Vlachopoulou M, Hamissa EM, AbdAlgaffar SA, Chatzis G. COVID-19 and the systemic use of aspirin in diabetics during hospitalization: a retrospective study. Presented at: 5th Annual Heart in Diabetes; Sept 10-12, 2021. Virtual. Poster 0024.
2. O’Brien MP, Forleo-Neto E, Musser BJ, et al. COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: subgroup analysis in participants with cardiovascular disease and diabetes. Presented at: 5th Annual Heart in Diabetes; Sept 10-12, 2021. Virtual. Poster 0099.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More